LOGIN  |  REGISTER
Viking Therapeutics

Latest Health Technology News

GE HealthCare management to present at upcoming investor conferences

August 21
Last Trade: 73.75 -0.12 -0.16

CHICAGO / Aug 21, 2025 / Business Wire / GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conferences. 2025 Wells Fargo Healthcare Conference – Thursday, September 4, 2025 at 8:45 am ET/7:45 am CT Morgan Stanley 23rd Annual Global Healthcare Conference – Tuesday, September 9, 2025 at 9:15 am ET/8:15 am CT Webcasts of these events can be accessed at the GE...Read more


VitalHub Closes $74.75 Million Bought Deal Public Offering with Full Exercise of Over-Allotment Option

August 20
Last Trade: 12.92 0.23 1.81

Toronto, Ontario--(Newsfile Corp. - August 20, 2025) - Vitalhub Corp. (TSX: VHI) (OTCQX: VHIBF) (the "Company" or "VitalHub") is pleased to announce that it has closed its previously announced bought deal offering pursuant to a press release dated August 15, 2025. A total of 5,885,828 common shares of VitalHub (the "Common Shares") were sold at a price of $12.70 per Common Share for total gross proceeds of approximately $74.75 million,...Read more


10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis

August 19
Last Trade: 13.34 -0.02 -0.15

First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology PLEASANTON, Calif., Aug. 19, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Xenium Protein, a powerful new addition to its Xenium Spatial platform that enables simultaneous RNA...Read more


Premier Reports Fiscal-Year 2025 Fourth-Quarter and Full-Year Financial Results

August 19
Last Trade: 25.71 0.15 0.59

Fourth-quarter total net revenue of $262.9 million was better than the company expected (total net revenue excluding Contigo Health* of $258.0 million) Fourth-quarter GAAP net income from continuing operations of $18.0 million, or $0.22 per fully diluted share Fourth-quarter adjusted EPS of $0.46, excluding Contigo Health* contributed to full-year adjusted EPS that was above the high end of the company’s guidance range Full-year net...Read more


OptimizeRx Announces Leadership Team Advancements to Accelerate Strategic Growth

August 19
Last Trade: 16.19 0.70 4.52

WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company’s Rule of 40 strategy—balancing sustained growth with increased profitability. These...Read more


Evolent Health Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock

August 18
Last Trade: 8.60 -0.36 -4.02

WASHINGTON, Aug. 18, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions ("Evolent"), today announced that it intends to offer $140.0 million aggregate principal amount of convertible senior notes due 2031, subject to market and other conditions. Evolent also expects to grant the initial purchasers in the proposed offering an option to purchase up...Read more


GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic® and Wegovy® for $499-Per-Month

August 18
Last Trade: 4.60 0.23 5.26

Until today, Ozempic® has not been available to eligible self-paying patients at this price SANTA MONICA, Calif. / Aug 18, 2025 / Business Wire / GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx,...Read more


IQVIA and Veeva Systems Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

August 18
Last Trade: 283.45 -0.57 -0.20

Global partnerships to help customers improve clinical and commercial efficiency and effectiveness RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif., Aug. 18, 2025 /PRNewswire/ -- IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced global clinical and commercial partnerships and the complete resolution of all pending legal disputes. Under the terms of the long-term agreement, customers can use software, data,...Read more


OneMedNet initiates new Subscription Revenue model in partnership with Circle CVI

August 18
Last Trade: 0.77 -0.01 -1.85

MINNEAPOLIS, Aug. 18, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced a long-term strategic partnership with Circle Cardiovascular Imaging Inc. (Circle CVI), a global leader in advanced cardiovascular imaging solutions. The collaboration reflects Circle CVI’s commitment to leveraging trusted, high-quality data to drive innovation in cardiac...Read more


So-Young Reports Unaudited Second Quarter 2025 Financial Results

August 15
Last Trade: 3.94 -0.12 -2.96

BEIJING, Aug. 15, 2025 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Total revenues were RMB378.7 million (US$52.9 million[1]), compared with...Read more


Teladoc Health Acquires Telecare, Expanding Access to Specialist and Allied Health Care for Australians in Public and Private Health

August 14
Last Trade: 7.17 -0.05 -0.69

MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced it has acquired Telecare, an innovative, Australian tech-enabled provider of specialist and allied health care via virtual delivery. Telecare operates Australia's leading virtual care clinic and provides software solutions to the healthcare sector. With over 300 virtual specialists in over 30...Read more


OneMedNet Reports 80% Reduction in Debt Enabling Focus On Growth

August 14
Last Trade: 0.77 -0.01 -1.85

MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announced its financial results for the second quarter ended June 30, 2025, including its significantly improved balance sheet. Second Quarter and First Half 2025 Financial Highlights Improved Balance Sheet: Due to the combination of debt conversions, vendor...Read more


VitalHub Announces $65 Million Bought Deal Public Offering

August 13
Last Trade: 12.92 0.23 1.81

TORONTO, Aug. 13, 2025 /CNW/ - VitalHub Corp. (the "Company" or "VitalHub") (TSX: VHI) is pleased to announce that it has entered into an agreement with Cormark Securities Inc. and National Bank Financial Inc. acting as co-lead underwriters, on behalf of a syndicate of underwriters (collectively, the "Underwriters") pursuant to which the Underwriters have agreed to purchase 5,118,111 Common Shares (the "Common Shares") from the...Read more


HEALWELL AI Reports Record Revenue Growth of 645% in Q2-2025 and Achieves First Quarter of Positive Adjusted EBITDA

August 13
Last Trade: 1.35 0.02 1.50

HEALWELL achieved quarterly revenue from continuing operations of $40.5 million in Q2-2025, 645% higher than the $5.4 million generated in Q2-2024. Revenue growth in the quarter was largely driven by the Orion Health acquisition, resulting in a record 1,064% year-over-year increase in the Company's Healthcare Software business compared to Q2-2024. During Q2-2025, HEALWELL reported positive Adjusted EBITDA of $1.9 million, compared to...Read more


Florida Hospital Selects SCWorx for Data Management for Workday Implementation

August 13
Last Trade: 0.28 -0.0002 -0.07

Tampa, FL, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (Nasdaq: WORX) today announced that it has signed another new healthcare provider for its SaaS service offering and Workday data management assistance. This new hospital customer is northeast Florida’s largest and most preferred health system.  The hospital is a not-for-profit healthcare provider with over 1,400 beds under management. In addition to the company’s data...Read more


NetraMark Appoints Jan Sedway as Senior Vice President of Clinical Science to Accelerate Growth and Market Leadership

August 12
Last Trade: 1.72 0.02 1.18

TORONTO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt:PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced the appointment of Jan Sedway, Ph.D., as Senior Vice President of Clinical Science. As NetraMark strategically expands its footprint in the pharmaceutical industry, this appointment reinforces the Company’s...Read more


TruBridge Announces Second Quarter 2025 Results

August 7
Last Trade: 19.71 0.32 1.65

MOBILE, Ala. / Aug 07, 2025 / Business Wire / TruBridge, Inc. (NASDAQ: TBRG), a healthcare solutions company, today announced financial results for the second quarter and six months ended June 30, 2025. Second Quarter 2025 Highlights* All comparisons are to the quarter ended June 30, 2024, unless otherwise noted Total bookings of $25.6 million compared to $23.3 million Total revenue of $85.7 million compared to $85.6...Read more


VitalHub Reports Second Quarter 2025 Results

August 7
Last Trade: 12.92 0.23 1.81

Annual Recurring Revenue (ARR)(1) up 55% YoY to $79.6 million Total Revenue up 47% YoY to $23.9 million Adjusted EBITDA(1) up 50% YoY to $6.3 million TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today it has filed its Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis report for the three and six months ended June...Read more


Doximity Acquires Pathway, a Leader in AI Clinical Reference

August 7
Last Trade: 64.27 -0.09 -0.14

$63M acquisition brings physician AI team and datasets to Doximity’s AI suite SAN FRANCISCO / Aug 07, 2025 / Business Wire / Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that it has acquired Pathway Medical Inc., a Montreal-based startup specializing in medical AI and evidence-based clinical reference. Physicians make up half of Pathway’s team. Over the past seven years,...Read more


Doximity Announces Fiscal 2026 First Quarter Financial Results

August 7
Last Trade: 64.27 -0.09 -0.14

Total revenues of $145.9 million, up 15% year-over-year Operating cash flow of $62.1 million, up 51% year-over-year Free cash flow of $60.1 million, up 52% year-over-year SAN FRANCISCO / Aug 07, 2025 / Business Wire / Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 first quarter ended June 30, 2025. “We began our year with strong profit growth and...Read more


Omada Health Reports Second Quarter 2025 Results

August 7
Last Trade: 0 0.00 0.00

Revenue of $61 million, up 49% 52% Member Growth and Significant Progress Toward Profitability SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) --  Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Highlights Total Members of 752,000, up 52% compared to the second quarter of 2024 Revenue of $61...Read more


Evolent Health Announces Second Quarter 2025 Results

August 7
Last Trade: 8.60 -0.36 -4.02

WASHINGTON, Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent exceeded...Read more


Solventum Reports Second Quarter 2025 Financial Results

August 7
Last Trade: 72.36 -0.49 -0.67

Reported sales increased 3.9%; organic sales increased 2.8% Increases full year organic sales growth outlook to +2.0% to +3.0% Increases full year earnings per share outlook to $5.80 to $5.95 ST. PAUL, Minn., Aug. 7, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales increased 3.9% to $2.2 billion; up 2.8% on an organic...Read more


10x Genomics Reports Second Quarter 2025 Financial Results

August 7
Last Trade: 13.34 -0.02 -0.15

PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2025. Recent Updates Revenue was $172.9 million for the second quarter. Excluding $27.3 million related to a patent litigation settlement, revenue was $145.6 million. Ended the second quarter with cash and cash equivalents and...Read more


Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2025

August 7
Last Trade: 3.80 0.08 2.15

Second Quarter Revenue Exceeded Guidance FRAMINGHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended June 30, 2025.  Second Quarter 2025 Financial Highlights: Revenue was $60.8 million, a decrease of 5% from $63.7 million in Q2...Read more


10x Genomics to Acquire Scale Biosciences

August 7
Last Trade: 13.34 -0.02 -0.15

Acquisition Will Further Expand Chromium's Capabilities PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has signed a definitive agreement to acquire Scale Biosciences, Inc., a leader in innovative and scalable single cell analysis. The acquisition provides 10x with key inventions and technologies that will advance innovation...Read more


Progyny Announces Second Quarter 2025 Results

August 7
Last Trade: 22.99 0.41 1.82

Reports Record Revenue of $332.9 Million, Reflecting 9.5% Growth Generates $55.5 Million in Quarterly Operating Cash Flow and Record $105.3 Million over the First Half of 2025 Raises Full Year Guidance to Reflect Continued Increase in Pacing of Member Engagement NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions,...Read more


Health Catalyst Reports Second Quarter 2025 Results

August 7
Last Trade: 3.02 0.10 3.25

SALT LAKE CITY, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2025. “For the second quarter of 2025, I am pleased by our strong financial results, including total revenue of $80.7 million and Adjusted EBITDA of $9.3 million, with...Read more


OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

August 7
Last Trade: 16.19 0.70 4.52

Q2 revenue of $29.2 million, increased 55% year-over-year Q2 gross profit increased 59% year-over-year to $18.6 million Paid down $4.5 million of principal on outstanding term loan during Q2 Increased full year 2025 guidance to a revenue range between $104 million and $108 million and adjusted EBITDA range between $14.5 million and $17.5 million WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the...Read more


Privia Health Reports Second Quarter 2025 Financial Results

August 7
Last Trade: 21.19 0.04 0.19

Very Strong First Half Performance Across All Key Operating and Financial Metrics Implemented Providers +13.8% and Practice Collections +18.5% compared to 2Q’24 Guidance Raised to Above High End of Range for Practice Collections, GAAP Revenue, Platform Contribution and Adjusted EBITDA c ARLINGTON, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the second quarter...Read more


Certara Reports Second Quarter 2025 Financial Results 

August 6
Last Trade: 10.79 0.10 0.94

Reiterates Full Year 2025 Financial Guidance RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. Second Quarter Highlights: Revenue was $104.6 million, compared to $93.3 million in the second quarter of 2024, representing growth of 12%. Software revenue was $46.7 million,...Read more


GoodRx Reports Second Quarter 2025 Results

August 6
Last Trade: 4.60 0.23 5.26

Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year SANTA MONICA, Calif. / Aug 06, 2025 / Business Wire / GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2025. Second Quarter 2025...Read more


Schrödinger Reports Second Quarter 2025 Financial Results

August 6
Last Trade: 19.66 0.30 1.55

Second Quarter Total Revenue of $54.8 Million, Software Revenue of $40.5 Million Maintains Full Year 2025 Revenue Growth Guidance and Lowers Operating Expense Guidance Company to Complete Phase 1 Data Package for SGR-1505 While Exploring Strategic Opportunities for Clinical Development Initial Clinical Data for SGR-3515 and SGR-2921 Expected in Fourth Quarter of 2025 NEW YORK / Aug 06, 2025 / Business Wire / Schrödinger, Inc....Read more


Claritev Reports Second Quarter 2025 Results

August 6
Last Trade: 29.20 0.00 0.00

Q2 2025 Revenues of $241.6 million, Net Loss of $62.6 million, and Adjusted EBITDA of $154.0 million (Adjusted EBITDA Margin of 63.8%) Full-year 2025 guidance updates to Revenue range (flat to +2% vs. 2024), Free Cash Flow range (usage of $20 million to generation of $20 million for year) and Capital Expenditures ($170 million to $180 million for year) MCLEAN, Va. / Aug 06, 2025 / Business Wire / Claritev Corporation (“Claritev” or...Read more


Kovo+ Announces Non-Brokered Private Placement

August 6
Last Trade: 0.05 0.00 0.00

Calgary, Alberta--(Newsfile Corp. - August 6, 2025) - Kovo+ Holdings Inc. (TSXV: KOVO) ("Kovo" or the "Company") is pleased to announce an offering of up to 827,820,000 units (each, a "Unit") on a non-brokered private placement basis for gross proceeds of up to approximately $41,391,000 (USD$30,000,000) (the "Offering") at a price of $0.05 per Unit. Each Unit will consist of (i) one common share of the Company and (ii) one-half of one...Read more


Amwell set to continue to enable U.S. Defense Health Agency healthcare teams to deliver connected and seamless in-person and virtual care for the Military Health System (“MHS”)

August 5
Last Trade: 7.01 0.16 2.34

U.S. Defense Health Agency awards Amwell, as part of a Leidos-led Partnership, an extension for the Military Health System’s Digital First Program BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading technology-enabled care platform provider, announced that as part of a Leidos-led partnership, it has been awarded an extension of its next-generation Digital First contract to power the digital transformation...Read more


Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study

August 5
Last Trade: 1.72 0.02 1.18

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced it has signed a contract with Asklepion Pharmaceuticals to deploy its NetraAI platform to analyze results from its pivotal Phase III pediatric clinical trial. The agreement covers the application of...Read more


SOPHiA GENETICS Reports Second Quarter 2025 Results

August 5
Last Trade: 3.62 0.04 1.12

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Revenue was $18.3 million, up 16% year-over-year Gross margin was 67.0% on a reported basis and 74.4% on an adjusted basis, up from 68.2% reported...Read more


SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

August 5
Last Trade: 3.62 0.04 1.12

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for...Read more


CareCloud Reports Second Quarter 2025 Results

August 5
Last Trade: 2.65 0.01 0.38

Delivers first quarter of positive GAAP EPS in Company’s history since going public, announces initial results from AI Initiative SOMERSET, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in healthcare technology and generative AI solutions, today announced strong financial results for the quarter ended June 30, 2025. CareCloud’s strategic execution, AI-driven...Read more


Amwell Announces Results for Second Quarter 2025

August 5
Last Trade: 7.01 0.16 2.34

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30. The company’s second quarter earnings report may be viewed at investors.amwell.com. Amwell will host a conference call to discuss its financial results today at 5 p.m. ET. The call can be accessed via a live audio...Read more


HealthStream Announces Second Quarter 2025 Results

August 4
Last Trade: 26.92 0.12 0.45

NASHVILLE, Tenn. / Aug 04, 2025 / Business Wire / HealthStream, Inc. (the "Company") (Nasdaq: HSTM), a leading healthcare technology platform company for workforce solutions, announced today results for the second quarter ended June 30, 2025. Second Quarter 2025 Revenues of $74.4 million in the second quarter of 2025, up 4.0% from $71.6 million in the second quarter of 2024, setting a new Company record for quarterly revenue Operating...Read more


CareCloud’s TalkEHR Approved for Use by Critical Access Hospitals, Unlocking $1.5B+ Inpatient Market

August 4
Last Trade: 2.65 0.01 0.38

SOMERSET, N.J., Aug. 04, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leading provider of healthcare technology and generative AI solutions, today announced that its electronic health record (“EHR”) platform has achieved ONC Health IT Certification specifically for Critical Access Hospitals (“CAHs”), a milestone officially granted on August 1, 2025. This...Read more


Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling

August 4
Last Trade: 10.79 0.10 0.94

RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU. Certara is the first company to receive EMA qualification for a PBPK modeling platform, and Simcyp is the only software to hold this designation. The recognition follows a rigorous multi-year,...Read more


Mobile-health Network Solutions Introduces AI Checker, Proprietary System That Critiques Quality of Doctors' Telehealth Notes

July 31
Last Trade: 1.06 0.02 1.92

'Major Step' in the Development of AI Doctor Singapore, Singapore--(Newsfile Corp. - July 31, 2025) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or "the Company"), a leading AI-powered digital health platform, today announced the deployment of its proprietary AI tool, AI Checker, an automated, cloud-based system providing doctors in primary care and nearly every medical specialty with immediate feedback on any omissions...Read more


Omnicell Announces Second Quarter 2025 Results

July 31
Last Trade: 31.85 0.10 0.31

Omnicell delivers strong second quarter financial results Results exceed previously issued second quarter 2025 guidance for revenues, non-GAAP EBITDA and non-GAAP EPS Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance FORT WORTH, Texas / Jul 31, 2025 / Business Wire / Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy and...Read more


Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

July 31
Last Trade: 10.79 0.10 0.94

Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy...Read more


Waystar Reports Second Quarter 2025 Results

July 30
Last Trade: 36.07 0.97 2.76

Q2 revenue growth of 15% year-over-year Q2 net income of $32.2 million and non-GAAP net income of $65.7 million Q2 net income margin of 12%; adjusted EBITDA margin of 42% Raising revenue and adjusted EBITDA guidance for 2025 LEHI, Utah and LOUISVILLE, Ky., July 30, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today reported results for the second quarter ended...Read more


Spok Reports Second Quarter 2025 Results

July 30
Last Trade: 17.75 -0.20 -1.11

Net Income and Adjusted EBITDA Continued Growth Strong Software Operations Bookings Drives Y-O-Y Increase in Software Revenue Company Increases Financial Guidance For 2025 PLANO, Texas / Jul 30, 2025 / Business Wire / Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced results for the second quarter ended June 30, 2025. In addition, the Company’s Board of Directors declared a regular...Read more


NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity

July 30
Last Trade: 1.72 0.02 1.18

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation (“Pentara”), a company offering clinical data analysis services to the pharmaceutical and biotechnology industries today announced they have entered into an agreement. NetraMark, in collaboration...Read more


GE HealthCare reports second quarter 2025 financial results

July 30
Last Trade: 73.75 -0.12 -0.16

Revenue growth was 3% year-over-year; Organic revenue growth* was 2% Net income margin was 9.7% versus 8.9% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 14.6% versus 15.3% Diluted earnings per share (EPS) were $1.06 versus $0.93 for the prior year; Adjusted EPS* was $1.06 versus $1.00 Cash flow from operating activities was $94 million versus $(119) million for the prior year; Free cash flow* was...Read more


Teladoc Health Reports Second Quarter 2025 Results

July 29
Last Trade: 7.17 -0.05 -0.69

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended June 30, 2025 (“Second Quarter 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended June 30, 2024 (“Second Quarter 2024”). Highlights Second Quarter 2025 revenue of $631.9 million, down 2%...Read more


Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design

July 29
Last Trade: 14.01 -0.03 -0.21

Researchers found 70% of compounds designed in ADMET Predictor demonstrated significant activity during in vitro testing RESEARCH TRIANGLE PARK, N.C. / Jul 29, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that...Read more


GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights

July 29
Last Trade: 120.71 0.59 0.49

Reported second quarter 2025 revenues of $102.7 million with 69% year-over-year growth of exome and genome test revenue Expanded adjusted gross margin to 71% and generated adjusted net income1 of $15.0 million for the second quarter 2025 Raised guidance to deliver between $400 and $415 million in revenue with between 48% to 52% full year growth in exome and genome revenue Announced American Academy of Pediatrics (AAP) now recommends...Read more


BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference

July 28
Last Trade: 1.23 0.009 0.74

GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, CEO, will participate in a fireside chat and one-on-one meetings at BTIG’s Annual Virtual...Read more


NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01

July 28
Last Trade: 1.72 0.02 1.18

TORONTO, July 28, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and AlgoTherapeutix SAS ("AlgoTx"), a clinical-stage biotechnology company developing first-in-class therapies for chemotherapy-induced peripheral neuropathy (CIPN) today announced they have entered into an agreement. Under...Read more


GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

July 28
Last Trade: 4.60 0.23 5.26

Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models SANTA MONICA, Calif. / Jul 28, 2025 / Business Wire / GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company’s Pharma...Read more


GE HealthCare launches new advanced digital X-ray system to enable access and increase efficiency in high throughput settings

July 24
Last Trade: 73.75 -0.12 -0.16

Definium™ Pace Select ET, a new floor-mounted digital X-ray system, enables access to affordable, high-quality medical imaging technology while easing workflow burdens in high-volume environments This new X-ray system, designed to act as a personal assistant for technologists, provides automation of in-room workflows and motorization of manual, repetitive tasks to increase throughput and reduce technologist learning curve CHICAGO /...Read more


Waystar to Acquire Iodine Software, Accelerating the AI-Powered Transformation of Healthcare Payments

July 23
Last Trade: 36.07 0.97 2.76

Extends Waystar's AI leadership into clinical intelligence software, unlocking greater value for clients and shareholders Highly recurring subscription-based business projected to be accretive to Waystar's financial profile Expected to expand Waystar's total addressable market by more than 15% Conference call to be held Wednesday, July 23, 2025, at 5:30 p.m. ET LEHI, Utah and LOUISVILLE, Ky., and AUSTIN, Texas, July 23, 2025...Read more


Veeva Systems OpenData and Veeva Network Enable Coordinated Customer Engagement for Boehringer Ingelheim

July 23
Last Trade: 283.45 -0.57 -0.20

PLEASANTON, Calif., July 23, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Boehringer Ingelheim is the latest top 20 biopharma to standardize customer data across more than 100 countries with Veeva OpenData and Veeva Network. Accurate and comprehensive customer reference data from OpenData will equip Boehringer Ingelheim's teams with the insights needed to engage healthcare professionals (HCPs) with relevant information,...Read more


Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on July 23

July 18
Last Trade: 1.23 0.009 0.74

GAITHERSBURG, Md., July 18, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics,, is pleased to invite investors to a webinar on July 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip...Read more


10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery

July 17
Last Trade: 13.34 -0.02 -0.15

Ambitious study will profile thousands of tumor samples to uncover novel biomarkers and therapeutic targets for cancer and inflammatory diseases PLEASANTON, Calif. and SINGAPORE, July 17, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS), today announced a research collaboration for the Target Inference from Spatialomics...Read more


Mobile-health Network Solutions Launches $300 Million At-the-Market Offering to Drive AI-Powered Healthcare and Pharmacy Delivery Expansion

July 17
Last Trade: 1.06 0.02 1.92

Singapore, Singapore--(Newsfile Corp. - July 17, 2025) - Mobile-health Network Solutions (Nasdaq: MNDR) ("MNDR" or "the Company"), a leading AI-powered digital health platform, today announced the launch of an At-the-Market (ATM) equity offering to raise up to US$300 million. This strategic fundraising initiative aims to accelerate the Company's vision of delivering affordable, intelligent, and integrated healthcare across high-growth...Read more


Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

July 17
Last Trade: 19.66 0.30 1.55

NEW YORK & CAMBRIDGE, Mass. / Jul 17, 2025 / Business Wire / Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) today announced an expansion of their exclusive research collaboration to include a new Janus kinase (JAK) target. The partnership was established in 2019 with a goal of leveraging Schrödinger’s advanced computational platform and Ajax’s structural biology insights to develop a pipeline of novel molecules, with a...Read more


CareCloud Launches AI-Driven, Fully Integrated Dermatology EHR to Streamline Workflows and Enhance Patient Care

July 17
Last Trade: 2.65 0.01 0.38

SOMERSET, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in healthcare technology and generative AI solutions for medical practices and health systems nationwide, today announced the launch of its fully integrated, AI-driven dermatology EHR, designed to streamline clinical workflows and collections, while enhancing patient engagement and improving financial...Read more


BullFrog AI Launches bfPREP, a New AI-Powered Data Preparation Module in Its BullFrog Data Networks Solutions Library

July 17
Last Trade: 1.23 0.009 0.74

New module addresses multi-billion-dollar data quality challenge in life sciences by automating data cleansing, standardization, and transformation for AI readiness Built for scale, security, and human in the loop domain expertise, the enterprise-wide solution is poised to transform drug development for the world’s largest biopharma organizations  GAITHERSBURG, Md., July 17, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings,...Read more


HEALWELL AI Provides Corporate Update Including Improved Performance in AI Business, Acquisition of Remaining Interest in Pentavere and Deeper Integration within the AI Business Segment

July 16
Last Trade: 1.35 0.02 1.50

HEALWELL announced improved performance for its core AI business segment with preliminary revenues expected to exceed $5 million for the first six months of 2025, reflecting a year-over-year increase of over 200% as compared to the same period last year. This strong performance is expected to lead to positive Adjusted EBITDA for the AI business segment during the first six months of the year. HEALWELL acquires remaining 49% of...Read more


Teladoc Health Launches Wellbound Employee Assistance Program (EAP)

July 15
Last Trade: 7.17 -0.05 -0.69

New offering will support employee mental health and well-being across a broad spectrum of needs—from everyday work-life challenges to complex mental health conditions NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the launch of Wellbound, a bold new employee assistance program (EAP) designed to empower a more engaged, healthier workforce. The new program,...Read more


Simulations Plus Invests in Clinical Development Technology Company Nurocor

July 14
Last Trade: 14.01 -0.03 -0.21

Investment to accelerate innovations in biopharma development through Corporate Development Initiative RESEARCH TRIANGLE PARK, N.C. / Jul 14, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in...Read more


Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results

July 14
Last Trade: 14.01 -0.03 -0.21

Updated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06 RESEARCH TRIANGLE PARK, N.C. / Jul 14, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial...Read more


Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause

July 10
Last Trade: 22.99 0.41 1.82

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced a new partnership with ŌURA, maker of the world’s leading smart ring, further empowering women to better understand and take action on their health through comprehensive data and personalized insights. By incorporating wearable data and insights from ŌURA into the care team...Read more


BullFrog AI Unveils BullFrog Data Networks™ Solutions Library, Expanding Scalable AI-Powered Biomedical Insight Platform to Large Enterprises

July 10
Last Trade: 1.23 0.009 0.74

New Data Networks Solutions Library includes native deployment support across Google Cloud Platform, Microsoft Azure, and Amazon Web Services Built for scale, security, and domain expertise, the enterprise-wide solution is poised to transform drug development for the world’s largest biopharma organizations GAITHERSBURG, Md., July 10, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the...Read more


Evolent Health announces key appointments to leadership team

July 9
Last Trade: 8.60 -0.36 -4.02

Dr. David Lim joins Evolent as chief clinical officer John Way joins Evolent as CFO, Performance Suite WASHINGTON, July 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced leadership additions to its clinical and financial teams, as it continues to drive innovation in specialty care. Physician, executive and startup...Read more


Claritev’s PHCS Network Receives Twelfth Consecutive NCQA Accreditation in Credentialing

July 8
Last Trade: 29.20 0.00 0.00

MCLEAN, Va. / Jul 08, 2025 / Business Wire / Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV) today announced that the PHCS Network, the largest primary PPO in the nation, received its 12th consecutive Accreditation in Credentialing from the National Committee for Quality Assurance (NCQA), a private nonprofit organization dedicated to improving health care quality. The PHCS Network is the only national independently...Read more


Certara Announces Expansion of Clinical Technology Collaboration with Merck

July 8
Last Trade: 10.79 0.10 0.94

Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and quality RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck’s use of the Certara Pinnacle 21 software platform to...Read more


Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

July 8
Last Trade: 21.19 0.04 0.19

Berberian brings significant technology leadership and cybersecurity expertise ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. “We are excited...Read more


VitalHub Announces Acquisition of Novari Health

July 7
Last Trade: 12.92 0.23 1.81

TORONTO, July 07, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has acquired (the “Acquisition”) Novari Health Inc. (“Novari”), a leading healthcare software provider of patient flow solutions based in Canada. Transaction Details VitalHub has acquired Novari for total up-front consideration of $43.6 million, plus potential performance-based consideration. The...Read more


PanGenomic Health Announces Financial Results for the 2024 Fiscal Year

July 2
Last Trade: 1.91 0.01 0.53

Vancouver, British Columbia, Canada – TheNewswire - July 2, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce that it has filed its audited annual consolidated financial statements for the financial year ended December 31, 2024 (the “2024 Year End Financial Statements”). The 2024 Year End Financial Statements, together with detailed information regarding the Company's financial results...Read more


Premier Expands Clinical Decision Support (CDS) Capabilities with Acquisition of IllumiCare

June 30
Last Trade: 25.71 0.15 0.59

IllumiCare’s cost attribution technology defines low-value care and makes costs transparent in real time, enabling improved financial performance. Compatible with 50-plus electronic medical record (EMR) systems, taps into a growing demand for solutions in outpatient and ambulatory settings. Unlocks potential growth opportunities across Premier’s service lines including clinical trial optimization, revenue cycle improvement and...Read more


Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

June 27
Last Trade: 19.66 0.30 1.55

Demonstrates the potential of SGR-1505 as a novel approach for diseases with high unmet medical need NEW YORK / Jun 27, 2025 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Waldenström macroglobulinemia that have failed at least two lines of...Read more


Veeva Systems and AWS Expand 10-Year Relationship

June 25
Last Trade: 283.45 -0.57 -0.20

AWS compute, database, and global infrastructure support Veeva’s industry cloud for life sciences PLEASANTON, Calif. & SEATTLE / Jun 25, 2025 / Business Wire / Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), and Veeva Systems (NYSE: VEEV), a leading provider of software, data, and business consulting for the life sciences industry, today announced an expansion of their long-standing collaboration. Veeva...Read more


GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics

June 25
Last Trade: 120.71 0.59 0.49

Data demonstrates that rapid genomic testing dropped the average time to a precise genetic diagnosis from almost ten months to 13 days Despite broad utilization in the study, rapid genomic sequencing in non-critical care inpatients yielded a diagnostic rate over 42%, comparable to critical care settings Study supports broader adoption of rapid genomic testing in the non-critical care inpatient setting to improve pediatric patient...Read more


First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

June 25
Last Trade: 7.33 0.28 3.97

The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence...Read more


FDA Approves Expanded Indications for GE HealthCare’s Vizamyl PET Imaging Agent for Beta Amyloid Detection, Enabling More Precise Care for Alzheimer’s Patients

June 24
Last Trade: 73.75 -0.12 -0.16

The FDA has approved an updated label for Vizamyl (flutemetamol F 18 injection), including quantification which enables a more continuous and objective measure of amyloid in the brain This approval also enables clinicians to use Vizamyl to monitor patient response to anti-amyloid therapies Other updates include now enabling the use of Vizamyl to predict development of dementia or other cognitive decline due to Alzheimer’s disease,...Read more


Progyny Adds Pelvic Floor Therapy, Continuing to Close Gaps in Care Across Women’s Health

June 24
Last Trade: 22.99 0.41 1.82

With nearly one third of women impacted by pelvic floor disorders, expanded care access and education from Progyny will help eliminate the silent suffering NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that it is adding pelvic floor therapy to its comprehensive offering of women’s health and family building solutions. With the...Read more


Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

June 24
Last Trade: 7.33 0.28 3.97

Dr. Kris Radcliff to Highlight MR Spectroscopy and Augmented Intelligence (AI)-Based Platform at State of Spine Surgery Think Tank BROOMFIELD, Colo., June 24, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain,...Read more


OneMedNet Announces Additional $3.7 Million of Funding in Private Placement Transactions and Approximately $11 Million in Reductions in Liabilities

June 24
Last Trade: 0.77 -0.01 -1.85

MINNEAPOLIS, June 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading provider of regulatory-grade imaging Real-World Data (iRWD), today announced that it has entered into agreements with accredited investors in private placement transactions at $0.42 per share of common stock that resulted in gross proceeds of approximately $3.7 million, before deducting fees and expenses payable...Read more


OptimizeRx Appoints CEO Steve Silvestro to Board of Directors

June 24
Last Trade: 16.19 0.70 4.52

WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company’s Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025. Mr. Silvestro...Read more


GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability

June 23
Last Trade: 120.71 0.59 0.49

A milestone in pediatric medicine, general pediatricians are now expected to play a more active role in initiating genetic testing Earlier use of exome and genome testing delivers better clinical outcomes and reduces costs across the U.S. healthcare system1 GeneDx will lead education and adoption efforts to end the diagnostic odyssey GAITHERSBURG, Md. / Jun 23, 2025 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering...Read more


GeneDx: Galatea Bio and Fabric Genomics Partner to Deliver Comprehensive Genetic Testing for Common Diseases

June 23
Last Trade: 120.71 0.59 0.49

MIAMI & OAKLAND, Calif. / Jun 23, 2025 / Business Wire / Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases. The initial offering will include an inherited cardiovascular gene panel based on American Heart Association (AHA)...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE